CGT Biotech/CDMO Transparency & Core Capabilities

This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech sharing what CGT developers should look for in a CDMO partnership, including transparency, data visibility, and capability rather than just capacity. The panelists reinforce that CGT companies should retain deep product knowledge, CMC strategy, quality oversight, and regulatory understanding in-house. The discussion closes with practical due-diligence questions for sponsors, such as asking about recent batch failures, actual slot utilization, and the team who will truly run the program.